United States · Biotechnology startup
United States · Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical-stage diabetes therapeutics company that designs and develops insulin-based therapies.
Funding reportedLast round: Undisclosed round
What company datasets say Diasome Pharmaceuticals raised
Funding, as reported
Reported in all$92Min dollars
Rounds7
Last roundUndisclosed round
Last round dateJun 2023
Investors listed6
SEC Form D$63M sold, 8 filings, last Aug 2024
Founders and team
From Diasome Pharmaceuticals's own website: 5 on the team.
- J. Lincoln ChapinVice President of Clinical Operations
- Linda RubinsteinChief Financial Officer
- Eric EdidinBoard Chairman
- Frank McCaneyDirector
- Thomas McDonaldDirector
On 3 portfolio pages
Investors who name them
Each firm lists Diasome Pharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Diasome Pharmaceuticals in front of investors. Or tell us what we have wrong.